Neurology · AntidepressantRegulatory Approvalregulatorymid-term

FDA Accepts ANDA for Viloxazine Hydrochloride by Appco Pharma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 12:32:59 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the ANDA for Viloxazine Hydrochloride by Appco Pharma is significant as it opens the door for new competition in the antidepressant market. Portfolio teams need to evaluate the potential impact on existing products and market dynamics. Regulatory context from FDA (FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry of Viloxazine Hydrochloride and its impact on existing products. The strongest clinical anchor is Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antidepressant, 8 regulatory and 2 competitive items passed relevance filtering for Appco Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS. This acceptance may position Appco Pharma to compete in the antidepressant market, particularly against established players.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG) (FDA). Entity match (appco pharma); Regulatory pathway relevance (nda). The acceptance of the ANDA indicates a step towards market entry, but ongoing monitoring of the review process and launch timelines is essential for compliance and strategic planning.

Key Risks

Elevated medium regulatory exposure for Appco Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Viloxazine Hydrochloride could disrupt market share among established antidepressant products, potentially affecting revenue streams for current players.
Lead sponsor: Sichuan Credit Pharmaceutical Co., Ltd.. An open-label, randomized, single dose study to assess dose proportionality and pharmacokinetic linearity in healthy participants under fasting condition.
Upside for Appco Pharma may improve if Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential market entry of Viloxazine Hydrochloride and its impact on existing products.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the ANDA review and any subsequent market launch timelines.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (appco pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — VILOXAZINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (appco pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TAPENTADOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
To Assess Dose Proportionality and Pharmacokinetic Linearity of Saninova Tablets in Healthy Participants Under Fasting Conditions
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Suction Mini-PCNL Versus Standard PCNL for the Management of 2-4cm Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Supplemental NDA for NUPLAZID by ACADIA PHARMS
Humanexa Signalsmedium relevance
Moderate corpus alignment

Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Appco Pharma
Viloxazine Hydrochloride

Commercial impact

medium

The entry of Viloxazine Hydrochloride could disrupt market share among established antidepressant products, potentially affecting revenue streams for current players.

Regulatory impact

medium

The acceptance of the ANDA indicates a step towards market entry, but ongoing monitoring of the review process and launch timelines is essential for compliance and strategic planning.

What to watch

Monitor the progress of the ANDA review and any subsequent market launch timelines.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.